Onsdag 28 Oktober | 18:13:39 Europe / Stockholm

All ägardata du vill ha finns i Holdings!

XVIVO - Early Heart support and a strong Q1

2023-04-25 08:15:00

Redeye updates our outlook after Q1. XVIVO’s result indicated a mix of organisational improvements and strong demand. Again XVIVO beat both our and market expectations. We make a minor positive sales revision driven by a positive Abdominal revision, improved gross margins, and a slightly higher OPEX level reflecting investments in ongoing and approaching launches. We increase our base case to SEK 405 (385) with a Bull of SEK 800 and a Bear of SEK 105.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/